Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Prostate cancer updates: TITAN and ENZAMET

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 2892

Prof Ian Davis and Prof Axel Merseburger

Professor Axel Merseburger and Professor Ian Davis discuss the latest data from the TITAN trial and ENZAMET trial presented at ASCO 2019 in Chicago, commenting on key efficacy and safety data and the distinguishing features of each trial. The experts also reflect on the ARCHES study presented at ASCO GU 2019 and the anticipated impact these trials will have on the clinical landscape.

Latest data from the TITAN trial
Key findings from the ENZAMET trial
Potential treatment combinations for patients with prostate cancer
Overview of the ARCHES trial

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 


Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation